- Home
- / Sangamo Therapeutics France
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Sangamo Therapeutics France financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
€2.2 M
FY, 2017
CreditSafe Score
?
Score changed on Jun 22, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| EUR | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|
| Revenue | 3.4M | 4.6M | 2.9M | 2.2M |
| Revenue growth, % | 35.5% | -36.4% | -24.2% | |
| General and administrative expense | 2.2M | 3.5M | 4.5M | 3.2M |
| Operating expense total | 10.1M | 14.3M | 15.0M | 11.6M |
| EBIT | (8.3M) | (11.3M) | (12.8M) | (10.5M) |
| EBIT margin, % | -241.8% | -244.0% | -433.6% | -470.0% |
| Interest income | 68.0K | 42.0K | 3.0K | 6.0K |
| Interest expense | 60.0K | 21.0K | 96.0K | |
| Pre tax profit | (8.3M) | (11.3M) | (13.6M) | (10.9M) |
| Net Income | (8.3M) | (11.3M) | (13.6M) | (10.9M) |